TECHNETIUM TC-99M PYROPHOSPHATE KIT - Generic Drug Details

What are the generic sources for technetium tc-99m pyrophosphate kit and what is the scope of freedom to operate?

Technetium tc-99m pyrophosphate kit is the generic ingredient in three branded drugs marketed by Sun Pharm Inds Inc, Bracco, and Curium, and is included in three NDAs. Additional information is available in the individual branded drug profile pages.

Two suppliers are listed for this compound.

Summary for TECHNETIUM TC-99M PYROPHOSPHATE KIT

US Patents:	0
Tradenames:	3
Applicants:	3
NDAs:	3
Finished Product Suppliers / Packagers:	2
Clinical Trials:	2
DailyMed Link:	TECHNETIUM TC-99M PYROPHOSPHATE KIT at DailyMed

Recent Clinical Trials for TECHNETIUM TC-99M PYROPHOSPHATE KIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Brigham and Women's Hospital	Phase 2
The Cleveland Clinic	Phase 4
Avid Radiopharmaceuticals	Phase 4

See all TECHNETIUM TC-99M PYROPHOSPHATE KIT clinical trials

Pharmacology for TECHNETIUM TC-99M PYROPHOSPHATE KIT

Drug Class	Radioactive Diagnostic Agent
Mechanism of Action	Radiopharmaceutical Activity

US Patents and Regulatory Information for TECHNETIUM TC-99M PYROPHOSPHATE KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Curium	TECHNESCAN PYP KIT	technetium tc-99m pyrophosphate kit	INJECTABLE;INJECTION	017538-001	Approved Prior to Jan 1, 1982	AP	RX	No	No
Bracco	PHOSPHOTEC	technetium tc-99m pyrophosphate kit	INJECTABLE;INJECTION	017680-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Sun Pharm Inds Inc	CIS-PYRO	technetium tc-99m pyrophosphate kit	INJECTABLE;INJECTION	019039-001	Jun 30, 1987	AP	RX	No	No

Last updated: February 15, 2026

Market Dynamics and Financial Trajectory for Technetium Tc-99m Pyrophosphate Kit

Market Overview

Technetium Tc-99m Pyrophosphate (PYP) kits are radiopharmaceuticals used predominantly for cardiac imaging, specifically to detect myocardial infarction and amyloidosis. The kits utilize technetium-99m, a radioactive isotope with a half-life of approximately 6 hours, sourced via generator systems. The global market for Tc-99m-based radiopharmaceuticals was valued at approximately $1.84 billion in 2021 and is projected to grow at a compound annual growth rate (CAGR) of 3-4% through 2027 (Analysis based on reports from MarketsandMarkets and GlobalData).

Market Drivers

• Rising Incidence of Cardiac Diseases: Increased prevalence of ischemic heart disease and myocardial infarction globally fuels demand for diagnostic imaging. The WHO reports that cardiovascular diseases caused 17.9 million deaths in 2019, representing 32% of all global deaths.

• Technological Advances: Development of high-resolution imaging devices and improved radiopharmaceutical formulations enhances diagnostic accuracy, making Tc-99m PYP kits more desirable.

• Regulatory Approvals: Expansion of indications for myocardial imaging and approvals by authorities such as the FDA and EMA facilitate market penetration.

• Limited Competition: Although other imaging agents exist, Tc-99m PYP kits remain favored for their specificity, availability, and established clinical protocols.

Market Constraints

• Radioisotope Supply Dependence: Tc-99m is produced using aging nuclear reactors and the molybdenum-99 (Mo-99) generator supply chain, susceptible to outages and geopolitical issues. The global supply chain faced disruptions during 2019-2021.

• Regulatory Barriers: Varying approval processes across regions delay market expansion.

• Environmental and Safety Concerns: Radioisotope handling requires strict safety protocols, impacting manufacturing costs and logistics.

Competitive Landscape

Company	Product Name	Market Share (Est.)	Notes
Cardinal Health	TechneLite Mo-99 generator	Leading supplier	Dominant provider of the Mo-99 supply chain.
Curium	Pyrophosphate kits	Moderate presence	Focused on niche cardiac imaging indications.
GE Healthcare	Tc-99m imaging kits	Significant market share	Offers integrated imaging solutions.

Financial Trajectory

Revenue Projections (2022-2027)

Year	Estimated Market Size (USD millions)	CAGR	Notes
2022	180-200	3-4%	Baseline based on recent market reports.
2023	186-208		Slight growth driven by increased cardiac diagnostics.
2024	192-216		Expansion into emerging markets.
2025	198-224		Regulatory approvals in Asia-Pacific regions.
2026	204-232		Entry of new competitors unlikely.
2027	210-240		Market stabilizes with steady growth.

Cost Dynamics

• Manufacturing Costs: Major expense components include procurement of Mo-99 generators, radioisotope labeling processes, and sterile, controlled environments. Cost increases are driven by supply chain disruptions and regulatory compliance.

• Pricing Trends: Generally, a slight decline in unit price expected due to increased competition and process efficiencies; however, scarcity of Mo-99 inflates prices sporadically.

Investment Outlook

• R&D Investment: Companies investing in alternative isotope production methods or generator technologies may reduce future cost pressures and supply vulnerabilities.

• Regulatory Favorability: Approvals for new indications and ease of registration in emerging markets factor positively into financial forecasts.

Regional Market Outlook

Region	Market Share	Growth Rate	Key Trends
North America	40%	3-4%	Mature market, driven by U.S. healthcare infrastructure.
Europe	25%	3-4%	Regulatory harmonization facilitates expansion.
Asia-Pacific	20%	5-6%	Rapid growth, emerging healthcare infrastructure, increasing cardiac disease prevalence.
Rest of World	15%	4-5%	Market entry driven by price sensitivity and infrastructure development.

Key Challenges & Risks

• Supply chain instability for Mo-99, affecting production capacity.
• Regulatory delays, particularly in markets with stringent approval frameworks.
• Competition from new imaging modalities and alternative radiotracers.

Strategic Opportunities

• Developing generator-independent isotopes or alternative production pathways.
• Diversifying indications, e.g., expanding into amyloidosis diagnosis.
• Collaborations with nuclear medicine centers to streamline adoption.

Key Takeaways

• The Tc-99m PYP kit market is expected to grow gradually, driven by increasing cardiovascular disease prevalence and technological upgrades.
• Supply chain vulnerabilities, primarily related to Mo-99 production, pose recurring risks.
• Regulatory and logistical challenges influence regional market expansion.
• Cost pressures are moderate; strategic R&D can mitigate supply risks and open new indications.
• Asia-Pacific region offers the fastest growth, driven by infrastructure improvements and disease burden.

FAQs

Q1: How does the supply chain for Mo-99 affect Tc-99m PYP kit availability?
A1: Reliance on aging reactors for Mo-99 production causes periodic shortages, impacting the supply of Tc-99m radiopharmaceuticals, leading to potential price fluctuations and availability issues.

Q2: Are there alternatives to Tc-99m PYP kits for cardiac imaging?
A2: Yes. Positron emission tomography (PET) tracers, like Flurpiridaz, and MRI-based techniques serve as alternatives but have limited widespread adoption due to cost and infrastructure needs.

Q3: What regulatory factors influence market growth?
A3: Approvals for new indications and region-specific registration procedures impact market expansion. Recent favorable policies in emerging markets can accelerate adoption.

Q4: How are technological advances impacting the market?
A4: Improved imaging devices, such as SPECT-CT hybrid systems, increase the resolution and diagnostic accuracy of Tc-99m PYP scans, reinforcing their clinical utility.

Q5: What future developments could disrupt current market trends?
A5: Breakthroughs in generator-independent isotope production, or the emergence of non-radioactive diagnostic alternatives, could reduce reliance on Tc-99m and alter market dynamics.

---

Citations:
[1] MarketsandMarkets. "Radionuclides Market by Type, Application, and Region - Global Forecast to 2027."
[2] GlobalData. "Radiopharmaceuticals Market Analysis."
[3] WHO. "Cardiovascular Diseases—Key Facts."